Spotlight: Chinese biotech chooses NY CRO for cancer trial

Beverly Hills, CA, cancer biopharma company Rich Pharmaceuticals has extended its agreement with Princeton, NJ-based CRO Theradex Systems to manage its clinical sites in the U.S. Through this continued deal, Theradex will lead Rich Pharma's new Phase I/II clinical for the treatment of acute myelocytic leukemia and myelodysplastic syndrome patients in the region. Release

> China-based biotech Henlius has chosen NY cloud software CRO Medidata to help it bring "operational efficiencies" to its ongoing Phase III cancer drug trial in its native country. Release

> HealthCarePoint, a Texas-based healthcare and clinical research networking-tech company, has completed global testing of its next-gen BlueCloud business model to help healthcare groups and CROs better manage clinical trials. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.